MedTrace Logo

Oral Aromatase Inhibitors Modify the Gut Microbiome

NCT05030038 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 25

Last updated 2026-04-13

No results posted yet for this study

Summary

The purpose of this research is to study the bacteria in participants' gut before receiving a medicine called an aromatase inhibitor for breast cancer and after participants receive medicine for breast cancer.

Conditions

Interventions

BIOLOGICAL

Fecal swab collection

Participants will collect fecal sample at home and either mail in the sample, or drop it off at the lab

BIOLOGICAL

Blood samples

Participants will have approximately 1 teaspoon of blood withdrawn from a vein, for research, on 2 different occasions. The total amount of blood withdrawn during the study will be approximately 2 teaspoons.

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Wake Forest University Health Sciences

    lead OTHER

Principal Investigators

  • Katherine Ansley, MD · Wake Forest Baptist Health Sciences

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-29
Primary Completion
2026-07-31
Completion
2026-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05030038 on ClinicalTrials.gov